May 17, 2023 / 06:05PM GMT
Greg Renza - RBC Capital Markets - Analyst
Welcome back, everyone, to the 2023 RBC Global Healthcare Conference. My name is Greg Renza, one of the senior biotech equity research analysts here at RBC. And we're pleased to be joined for this session by Verastem.
Joining us from the company is the Chief Executive Officer, Brian Stuglik; and the Chief Scientific Officer, Jon Pachter. So it's great to have you guys.
Questions and Answers:
Greg Renza - RBC Capital Markets - AnalystBrian, I think I just wanted to just start by having you give us a brief overview of Verastem -- a great deal going on. Many folks are familiar with the name of the company, but there are some interesting developments with your lead asset. And I think bringing investors up to speed is worthwhile.
Brian Stuglik - Verastem, Inc. - CEO
Yeah, sure. Great. Thanks, Greg. So several years ago, we pivoted the company. We started with the product -- our company was founded on a product called defactinib back in 2012. And again, we did some
Trustpilot
